Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MONITOR
August 23, 2004
- NEW PRODUCTS
August 23, 2004
- Meet the Leaders (35)
August 23, 2004
- Precautions Revised for 4 Drugs Including Clarithromycin
August 23, 2004
- Daiichi to Return to Track of Growth via Structural Reform
August 23, 2004
- REGULATORY NEWS IN BRIEF
August 23, 2004
- Aiming at Sales of \120 Bil. in 2010: Mr Crenshaw of Eli Lilly Japan
August 23, 2004
- NHO Plans to Improve Domestic Clinical Trials
August 23, 2004
- Eisai to Triple Production of Aricept, Pariet at Kashima Plant
August 23, 2004
- BULLETIN
August 23, 2004
- Mr Komine of MPC Stresses Medicoeconomic Benefits of Zione
August 23, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- Chugai to Strengthen Antibody Drug Business by Transferring OTC Business to Lion
August 23, 2004
- OTC NEWS IN BRIEF
August 23, 2004
- BUSINESS NEWS IN BRIEF
August 23, 2004
- Korosho Calls For Proper Use of Cypher Stents, Ticlopidine
August 23, 2004
- WEB SITE NEWS
August 23, 2004
- Terumo Ties Up with Spenser Technologies of the US in Diagnosis of Cerebral, Cardiac Diseases
August 23, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…